Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as a targeted therapy for particularly aggressive cancers.
The Company’s lead compound is currently in late stage preclinical development for glioblastoma, a deadly cancer of the central nervous system.
Hemispherian’s targeted therapeutics act on an entirely new mechanism of action. These drugs work by restoring a cancer cell’s normal epigenetic complement. The drug-induced restoration of this modified DNA base triggers the DNA damage response and results in cancer cytotoxicity. Treatment with these compounds is highly targeted towards cancers and is well tolerated in normal tissues.
We’re receiving support by several Norwegian and European public entities. We are always looking for new partners to further strengthen our network. Contact us if you would like to help us bringing our drugs into clinics.
